

Journal of Visualized Experiments

Seeding and implantation of a biosynthetic tissue-engineered tracheal graft in a mouse model --Manuscript Draft--

Article Type:	Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59173R2
Full Title:	Seeding and implantation of a biosynthetic tissue-engineered tracheal graft in a mouse model
Keywords:	electrospinning; synthetic scaffold; medicine; tracheal graft; cell seeding; biomaterials; tracheal diseases
Corresponding Author:	T Dr. Chiang
Corresponding Author's Institution:	
Corresponding Author E-Mail:	Tendy.Chiang@nationwidechildrens.org
Order of Authors:	Tendy Chiang
	Matthew G. Wiet
	Audrey White
	Sayali Dharmadhikari
	Susan D. Reynolds
	Jed Johnson
	Christopher K. Breuer
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Columbus, OH USA

TITLE:

Seeding and Implantation of a Biosynthetic Tissue-engineered Tracheal Graft in a Mouse Model

AUTHORS AND AFFILIATIONS:

Matthew G. Wiet MS^{1,2*}, Audrey White^{1,2*}, Sayali Dharmadhikari MS^{1,3}, Susan D. Reynolds PhD⁴,
Jed Johnson PhD⁵, Christopher K. Breuer MD^{3,6}, Tendy Chiang MD^{1,3}

¹Department of Otolaryngology Head & Neck Surgery, Nationwide Children's Hospital, Columbus, OH, USA

²The Ohio State University College of Medicine, Columbus, OH, USA

³Center for Regenerative Medicine, Research Institute at Nationwide Children's Hospital, Columbus, OH, USA

⁴Center for Perinatal Research, Nationwide Children's Hospital, Columbus, OH, USA

⁵Nanofiber Solutions, Inc., Columbus, OH, USA

⁶Department of Pediatric Surgery, Nationwide Children's Hospital, Columbus, OH, USA

*These authors contribute equally to the manuscript.

Corresponding Author:

Tendy Chiang

Tendy.Chiang@nationwidechildrens.org

E-mail Addresses of Co-authors:

Matthew Wiet (Matthew.Wiet@osumc.edu)

Audrey White (Audrey.White@osumc.edu)

Sayali Dharmadhikari (Sayali.Dharmadhikari@nationwidechildrens.org)

Susan D. Reynolds (Susan.Reynolds@nationwidechildrens.org)

Jed Johnson (Jed.Johnson@nanofibersolutions.com)

Christopher K. Breuer (Christopher.Breuer@nationwidechildrens.org)

KEYWORDS:

electrospinning, synthetic scaffold, medicine, tracheal graft, cell seeding, biomaterials, tracheal diseases

SUMMARY:

Graft stenosis poses a critical obstacle in tissue engineered airway replacement. To investigate cellular mechanisms underlying stenosis, we utilize a murine model of tissue engineered tracheal replacement with seeded bone marrow mononuclear cells (BM-MNC). Here, we detail our protocol, including scaffold manufacturing, BM-MNC isolation, graft seeding, and implantation.

ABSTRACT:

Treatment options for congenital or secondary long segment tracheal defects have historically been limited due to an inability to replace functional tissue. Tissue engineering holds great promise as a potential solution with its ability to integrate cells and signaling molecules into a 3-dimensional scaffold. Recent work with tissue engineered tracheal grafts (TETGs) has seen some success but their translation has been limited by graft stenosis, graft collapse, and delayed

epithelialization. In order to investigate the mechanisms driving these issues, we have developed a mouse model for tissue engineered tracheal graft implantation. TETGs were constructed using electrospun polymers polyethylene terephthalate (PET) and polyurethane (PU) in a mixture of PET and PU (20:80 percent weight). Scaffolds were then seeded using bone marrow mononuclear cells isolated from 6-8 week-old C57BL/6 mice by gradient centrifugation. Ten million cells per graft were seeded onto the lumen of the scaffold and allowed to incubate overnight before implantation between the third and seventh tracheal rings. These grafts were able to recapitulate the findings of stenosis and delayed epithelialization as demonstrated by histological analysis and lack of Keratin 5 and Keratin 14 basal epithelial cells on immunofluorescence. This model will serve as a tool for investigating cellular and molecular mechanisms involved in host remodeling.

INTRODUCTION:

Long-segment tracheal defects can present as rare congenital conditions such as complete tracheal rings and tracheal agenesis, as well as trauma, malignancy, and infection. When exceeding 6 cm in adults or 30% of the tracheal length in children, these defects cannot be treated by surgical reconstruction. Attempts to replace the airway with autologous tissue, cadaveric transplants, and artificial constructs have been plagued by chronic infection, granulation, mechanical failure, and stenosis.

Tissue engineered tracheal grafts (TETGs) can potentially address these problems while avoiding the need for life-long immunosuppression. In the last decade, TETGs have been tested in animal models and utilized clinically in rare instances of compassionate use¹⁻³. In both clinical and large animal studies, post-operative recovery from tissue engineered airway replacement required numerous interventions to combat stenosis (defined as >50% luminal narrowing) and maintain airway patency. Additional TETG work has sought to reduce this stenosis through evaluating the role of cell seeding choice, vascularization and scaffold design. Cell seeding choices and scaffold design aimed at restoring native trachea structure/function have mainly been focused on respiratory epithelial cells and chondrocytes seeded on various resorbable, non-resorbable and decellularized scaffolds. As vascularization likely plays an major role in the development of stenosis, other groups have focused on optimizing *in vitro* or heterotopic models to expedite revascularization or neoangiogenesis⁴. Nonetheless, achieving successful vascularization while also maintaining a mechanically competent and functional TETG remains a challenge. Despite recent advances, minimizing stenosis remains a critical obstacle to clinical translation.

To investigate this histopathological response to TETG implantation *in vivo*, we developed an ovine model of tissue engineered tracheal replacement. The graft was composed of a mixed polyethylene terephthalate (PET) and polyurethane (PU) electrospun scaffold seeded with bone marrow-derived mononuclear cells (BM-MNCs). In this small cohort, we demonstrated that seeded autologous BM-MNCs accelerated re-epithelialization and delayed stenosis⁵. Although seeding with autologous BM-MNCs improved survival, the cellular mechanism by which BM-MNCs modulate the formation of functional neotissue remains unclear.

Investigation on the cellular level required development of a murine model of tissue engineered tracheal replacement. Similar to the ovine study, we utilized a PET:PU electrospun scaffold

seeded with BM-MNCs. Consistent with the ovine model, TETG stenosis developed over the course of the first two weeks following implantation^{1-3,5}. This suggested that the murine model recapitulated the pathology observed previously, enabling us to further interrogate the cellular mechanisms underlying airway stenosis.

In this report, we detail our protocol for tissue engineered tracheal replacement in the mouse model including scaffold manufacturing, BM-MNC isolation, graft seeding, and implantation (Figure 1, Figure 2).

PROTOCOL:

All methods described here have been approved by the Institutional Animal Care and Use Committee (IACUC) at Nationwide Children's Hospital.

1. Scaffold Manufacturing

1.1. Prepare a polymer nanofiber precursor solution by: 1) dissolving 8 wt% PET in 1,1,1,3,3,3-hexafluoroisopropanol and heating the solution to 60 °C and by 2) dissolving 3 wt% PU in 1,1,1,3,3,3-hexafluoroisopropanol at room temperature.

1.2. Once cooled, combine the solutions to create a final polymer mixture of PET and PU (20:80).

1.3. Electrospin the PET+ PU solution onto a stainless steel rod (1 mm diameter) utilizing a 20G blunt tip needle on a 60 mL syringe filled with the PET:PU solution using a high-voltage DC power supply set to +14 kV on the needle, another high-voltage DC power supply set to -3 kV, a 5 mL/h flow rate, and a 20 cm tip-to-substrate distance. Rotate the rod at 350 rpm during fiber deposition.

1.4. Continue electrospinning until the desired scaffold wall thickness of 300 µm is achieved. Slide the scaffold off the rod, then hold it under vacuum overnight to remove any residual solvent.

1.5. Sterilize the scaffold using an ultraviolet light dosage of 350 mJ/cm² prior to implantation.

2. Bone Marrow Mononuclear Cell (BM-MNC) Harvesting

2.1. Euthanize a 6-8 weeks old, female, C57BL/6 mouse with a cocktail of ketamine (200 mg/kg), xylazine (20 mg/kg) and ketoprofen (10 mg/kg). Check for complete euthanasia by tail-pinch method.

2.2. Remove the skin over the femurs and tibias to expose bone using fine scissors and micro-Adson forceps. Use Dumont #5 forceps and Dumont #5/45 forceps to remove the fascia and the tendons. Separate the bones and cut each of them on both the ends. Using a 5 mL syringe and a 25G needle, flush the bone marrow in a Petri dish containing 30 mL of Rosewell Park Memorial

Institute (RPMI) media. Filter this RPMI with bone marrow through a 70 μ m nylon cell strainer into a 50 mL tube.

2.3. In a Biosafety Cabinet, place 5 mL of polysucrose and sodium diatrizoate in a 15 mL tube. Gently add the RPMI containing bone marrow mononuclear cells down the side of the tube to avoid mixing of the two layers. Centrifuge at 461 x *g* for 30 min with “Brake 1” at 24 °C.

NOTE: On our centrifuge, brake 1 stands for the longest run out time during deceleration.

2.4. Out of the three layers formed, discard the top (pink) layer of plasma and collect the middle (clear) layer consisting of the bone marrow mononuclear cells. Discard the precipitate of red blood cells.

2.5. Dilute the bone marrow mononuclear cells (BM-MNC) in phosphate buffered saline (PBS) in a 1:1 ratio and centrifuge at 461 x *g* for 10 min with “Brake 9” at 24 °C.

2.6. Remove the supernatant and dilute the pellet with 5 mL of PBS. Centrifuge at 461 x *g* for 10 min with “Brake 9” at 24 °C.

2.7. Remove the supernatant and dilute the pellet with ~10 mL of RPMI.

2.8. Dilute 10 μ L of the BM-MNC solution with an equal volume of 0.4% trypan blue in a 1 mL tube. Place 10 μ L of the solution in a cell counting chamber slide. Count the cells using an automated cell counter. Repeat the step and calculate the average number of cells.

NOTE: An average cell count of 1×10^8 cells was obtained from the use of two donor mice. This would be equivalent to two femurs, and two tibias that bone marrow is isolated from.

2.9. Centrifuge the BM-MNC solution at 461 x *g* for 10 min with “Brake 9” at 24°C. Remove the supernatant and dilute the cell concentration to 10^7 cells/graft.

NOTE: We have studied seeding efficiency between 1, 10 and 100 million cells and found that 10 million cells per graft yields the highest seeding efficiency.

3. Cell Seeding on the Grafts

3.1. Measure the lengths of the scaffolds and if needed, cut them to a length of 5 mm.

3.2. Pre-wet the scaffold with 5 μ L of RPMI for 5 min. Remove the RPMI.

3.3. Add 5 μ L of the BM-MNC solution to the lumen of the scaffold for 10 min.

3.4. Pass a 21G needle through the lumen of the graft and incubate the graft in 1000 μ L of RPMI overnight at 37 °C in an incubator.

4. Graft Implantation

NOTE: Care should be taken to maintain aseptic technique during the graft implantation procedure.

4.1. Use 6-8-week-old female C57BL/6 mice as recipients for the cell seeded grafts. Inject enrofloxacin (10mg/kg) subcutaneously 24 h before surgery and just before incision.

4.2. Weigh the mouse and administer a 0.1 mL/10 g dose of the anesthetic cocktail of ketamine (100 mg/kg), xylazine (10 mg/kg) and ketoprofen (5 mg/kg) intraperitoneally.

4.3. Check if the plane of anesthesia has been achieved by tail-pinch method. On confirming the level of sedation, apply a sterile ophthalmic ointment to the eyes and clip the hair on the surgical site from chin to clavicles. Place the animal on a pad in a dorsal recumbent position. Disinfect the surgical site using first a povidone-iodine prep pad, followed by an alcohol prep pad (70% alcohol), and once more a povidone-iodine prep pad.

4.4. Place the animal under the dissecting microscope with its head away from the surgeon. Make a midline incision ranging from the clavicles to the hyoid bone with the help of fine scissors and micro-Adson forceps. Clean the fascia with Dumont #5 and Dumont #7 fine forceps, along with a sterile cotton swab if needed, and insert a self-retaining Colibri retractor.

4.5. Open the strap muscles (**Figure 3A**) with Dumont #5 and Dumont #7 fine forceps to expose the thyroid cartilage, cricoid cartilage and the trachea. Bluntly separate the trachea from the recurrent laryngeal nerves running parallel on either side, followed by circumferential separation of the trachea from the esophagus (**Figure 3B**).

4.6. Using a 20G needle and surgical marker, stain the anterior portion of the trachea.

4.7. Identify the trachea and make an incision below the third tracheal cartilage ring and resect a three-ring section of trachea using a pair of Vannas-Tubingen spring scissors and a pair of Dumont #7 fine forceps. Holding it with the fine curved forceps, ligate the distal trachea to the sternum using sterile 9-0 nylon suture to create a temporary tracheostomy (**Figure 3C**).

4.8. With a 20G needle and a surgical marker, stain the graft to represent the anterior portion.

4.9. Implant the graft inserting the proximal-posterior, proximal-lateral and proximal-anterior sutures, in that order using 9-0 sterile nylon suture (**Figure 3D**), Dumont #7 fine forceps and a needle holder.

4.10. Turn the animal 180° to place its tail away from the surgeon. Release the temporary tracheostomy. At a distance of 5 mm, make a lateral incision to facilitate distal anastomosis.

4.11. Complete the distal anastomosis by placing the sutures in the similar fashion as the proximal anastomosis.

4.12. Re-approximate the graft position and the strap muscles. Close the incision using 9-0 sterile nylon sutures in a running pattern.

4.13. Inject 0.1 mL of buprenorphine (0.1 mg/kg) subcutaneously and place the animal in a recovery cage placed on a heating pad without other animals in the cage.

4.14. Observe the mouse until it is conscious and able to ambulate, then transfer the mouse to a new cage with soft bedding, moist chow and medicated water (ibuprofen, 30 mg/kg) for 48 h. After this time period, return the mouse to a normal cage with other mice.

NOTE: Mice that maintain respiratory distress or decreased activity after implantation are observed by laboratory and/or animal staff in a 32 °C incubator. If this continues for more than 48 h, then the mice should be euthanized.

5. Histology and Immunohistochemistry

NOTE: Hematoxylin and eosin stains were performed using standard technique by Nationwide Children's Hospital Morphology Core. Immunohistochemistry was performed according to the below steps.

5.1. Deparaffinize the slides using 1) xylene for 5 min, 2) xylene for 5 min, 3) 100% ethanol for 5 min, 4) 90% ethanol for 5 min, 5) 70% ethanol for 5 min, 6) distilled H₂O (dH₂O) for 5 min.

5.2. Submerge the slides in citrate buffer and place in water-filled pressure cooker. Heat for 10 min then allow to cool to room temperature. Wash with 0.1% bovine serum albumin in PBS (BSA-PBS) for 5 min. Rinse with dH₂O.

NOTE: Heating can also be done with a hot water bath or microwave for 15 min.

5.3. Incubate the slides with 3% normal goat serum in PBS for 1 h at room temperature. Wash with 0.1% BSA-PBS for 5 min. Incubate in primary antibody with concentrations for keratin 5 (1:1000)⁶, keratin 14 (1:250)⁶ and F4/80 (1:100)⁷ for 18 h overnight at 4 °C.

5.4. Wash with 0.1% BSA-PBS twice for 10 min each wash. Incubate with appropriate secondary antibody at concentration of 1:500 for K5/K14 and 1:300 F4/80 for 1 h at room temperature. Wash with 0.1% BSA-PBS twice for 10 min each wash.

5.5. Mount using 4', 6-diamidino-2-phenolindole (DAPI) containing mounting media and glass cover slips. Allow to sit for 30 min before imaging.

REPRESENTATIVE RESULTS:

Figure 1 illustrates a schematic of TETG seeding and implantation. Bone marrow was harvested from C57BL/6 mice and cultured *in vitro*. BM-MNCs were isolated by density centrifugation and seeded onto the TETG. Seeded TETGs were implanted into a syngeneic C57BL/6 recipient mouse.

Figure 2 is an overview of the PET:PU TETG scaffold manufacturing process. PET:PU solution was electrospun onto a 20G blunt needle in order to achieve a final TETG wall thickness of 300 μm and lumen diameter of 1 mm to approximate the native mouse trachea. The surface of the TETG can be seen in the scanning electron microscope image with animated mononuclear cells.

The surgical implantation procedure is outlined in **Figure 3** with the most important steps shown. **Figure 3** shows the separation and retraction of strap muscles (**Figure 3A**) and subsequent circumferential isolation of the trachea from surrounding tissues (**Figure 3B**). **Figure 3C** demonstrates the distal temporary tracheostomy with attachment to the sternal notch to ensure patent airway during the procedure. Finally, **Figure 3D** shows the graft in place after final anastomoses.

In a small cohort study, four mice were implanted with TETGs and followed over a two-week period. A few basal epithelial cells can be appreciated in basal cell keratin 5 and 14 staining shown in **Figure 4A-C**. The combined image (**Figure 4C**) shows the presence of basal cells on the luminal surface of the graft at 7 days after implantation.

Three out of the four animals showed signs of respiratory distress and stridor, two of which required early termination on post-operative days 1 and 7. Upon explantation and histological analysis, graft stenosis was identified as the main contributing factor to the complications. **Figure 5A-E** gives a view of the post-operative day 7 animal's stenotic region of the TETG. Of note, telescoping of the graft and native trachea is a common finding due to surgical technique. The low (**Figure 5A**) and high (**Figure 5B**) powered photomicrograph of the stenosis demonstrates one of the main complications of TETG implantation. **Figure 5C** is a representative F4/80 stain revealing the presence of host macrophages in the stenotic region. **Figure 5D** and **Figure 5E** again show the basal epithelial cell markers keratin 5 and 14 at the stenotic region of the graft.

FIGURE AND TABLE LEGENDS:

Figure 1: TETG seeding and implantation schematic. Bone marrow-derived mononuclear cells obtained from a donor mouse were isolated by density centrifugation, seeded onto a scaffold, and implanted into a recipient mouse.

Figure 2: Electrospinning of tissue engineered tracheal graft. (A) Overview of electrospinning process. (B) 20G blunt needle used as rotating mandrel to manufacture mouse scaffolds. (C) Animated SEM schematic of scaffold surface after mononuclear cells have been added.

Figure 3: Overview of surgical implantation of scaffold. (A) Separation and retraction of strap muscles. (B) Circumferential separation of the trachea from surrounding tissues/organs. (C) Creation of temporary tracheostomy and attachment to the sternal notch. (D) Implanted graft after proximal and distal anastomoses. Scale bar = 2 mm.

Figure 4: Histological evidence of basal epithelial cells. Merged immunofluorescence image of basal cell markers keratin 5 (A) and keratin 14 (B) and the merged keratin 5 and keratin 14 (C). The arrow denotes epithelial tissue growth at the scaffold-native tissue junction. The lumen and scaffold are denoted with (*) and (†), respectively. Scale bar = 50 µm.

Figure 5: Histological visualization of stenotic region of graft. (A) Longitudinally sectioned H&E of length of trachea including graft with distal stenosis near the anastomosis. Scale bar = 500 µm. High power images of selected stenotic region using H&E (B), F4/80 (C), Keratin 5(D), and Keratin 14 (E). Scale bars = 50 µm.

DISCUSSION:

Development of a mouse model for tissue engineered tracheas is essential in understanding the factors that have limited clinical translation of the TETGs; namely graft collapse, stenosis and delayed epithelialization⁴. A few factors that contribute to these limitations include selection of graft material, the manufacturing process, scaffold design and cell seeding protocols. This model allows for faster evaluation of these factors in order to understand the cellular and molecular mechanisms affecting them.

We have shown here the presence of epithelial cells (**Figure 4**) as well as the ability of the model to recapitulate graft stenosis (**Figure 5**); however, successful use of the model depends on a few key steps during the implantation process. First, during initial incision and isolation of the mouse trachea, it is essential to avoid injury or stretching of the adjacent recurrent laryngeal nerves located in the tracheoesophageal groove. Another important factor during resection of the native trachea is to avoid any damage to the esophagus sitting posterior to the trachea.

Endotracheal intubation can be avoided by creating a temporary tracheostomy to allow airflow during the procedure. It is important, however, to keep anything (i.e., tissue) from blocking the temporary distal tracheostomy as well as maintaining the trachea outside of the body cavity to facilitate respiration. Graft telescoping is a common occurrence in graft implantations and may be seen on histological sections.

Other animal models that have been utilized in studying TETGs include New Zealand white rabbits, dogs, rats, pigs, and sheep⁸⁻¹¹; many of which can be cost prohibitive and lack comprehensive quantification methods (i.e., ELISAs, Immunohistochemistry antibodies, PCR primers, etc.) and/or transgenic options. Thus, large animal models used are often underpowered or are unable to answer mechanistic questions. The use of transgenic mice in this model as well as the straightforward graft design and manufacturing process make it ideal for faster mechanistic studies looking at graft stenosis and re-epithelialization. The orthotopic transplantation used in this TETG model provides the benefit of the graft being exposed to the external environment and the ability to potentially measure epithelial cell differentiation. However, it is important to remember that translation of transgenic studies to large animal models and clinical trials can be difficult. Furthermore, while this mouse model can potentially be more cost effective in increasing population size, it does not currently have the same clinical

diagnostic and therapeutic capabilities as in larger animal models (i.e., bronchoscopy with endoscopic interventions) making it challenging to compare between outcomes.

Future work with this model will be focused on investigating optimal cell seeding conditions (cell type, density, etc.) and its role in limiting graft stenosis and improving epithelialization. Scaffold design is also an important variable that has significant effects on graft performance *in vivo* and will require more investigation as to the optimal scaffold material and microstructure. These studies will assist in the translation of TETGs to large animal models and eventually human clinical trials.

ACKNOWLEDGMENTS:

We would like to acknowledge Robert Strouse and the Research Information Solutions & Innovations division at Nationwide Children's Hospital for their support in graphic design. This work was supported by a grant from the NIH (NHLBI K08HL138460).


DISCLOSURES:


The authors declare no competing financial interests.


REFERENCES:


1. Macchiarini, P., et al. Clinical transplantation of a tissue-engineered airway. *The Lancet* **372**, (9655), 2023–2030 (2008).
2. Jungebluth, P., et al. Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: A proof-of-concept study. *The Lancet* **378**, (9808), 1997–2004 (2011).
3. Elliott, M. J., et al. Stem-cell-based, tissue engineered tracheal replacement in a child: A 2-year follow-up study. *The Lancet* **380**, (9846), 994–1000 (2012).
4. Chiang, T., Pepper, V., Best, C., Onwuka, E. & Breuer, C. K. Clinical Translation of Tissue Engineered Trachea Grafts. *Annals of Otology, Rhinology and Laryngology* **125**, (11), 873–885 (2016).
5. Clark, E. S., et al. Effect of cell seeding on neotissue formation in a tissue engineered trachea. *Journal of Pediatric Surgery* **51**, (1), 49–55 (2016).
6. Cole, B. B., Smith, R. W., Jenkins, K. M., Graham, B. B., Reynolds, P. R. & Reynolds, S. D. Tracheal basal cells: A facultative progenitor cell pool. *American Journal of Pathology* **177**, (1), 362–376 (2010).
7. Onwuka, E., et al. The role of myeloid cell-derived PDGF-B in neotissue formation in a tissue-engineered vascular graft. *Regenerative Medicine* **12**, (3), 249–261 (2017).
8. Grimmer, J. F., et al. Tracheal reconstruction using tissue-engineered cartilage. *Archives of Otolaryngology - Head and Neck Surgery* **130**, (10), 1191–1196 (2004).
9. Wood, M. W., Murphy, S. V., Feng, X. & Wright, S. C. Tracheal reconstruction in a canine model. *Otolaryngology - Head and Neck Surgery (United States)* **150**, (3), 428–433 (2014).
10. Haag, J., et al. Biomechanical and angiogenic properties of tissue-engineered rat trachea using genipin cross-linked decellularized tissue. *Biomaterials* **33**, (3), 780–789 (2012).
11. Best, C. A., et al. Designing a tissue-engineered tracheal scaffold for preclinical evaluation.


397 *International Journal of Pediatric Otorhinolaryngology* **104**, 155–160 (2018).
398











Name of Material/ Equipment	Company	Catalog Number	Comments/Description
0.9% Sodium chloride injection	APP Pharmaceuticals	NDC 63323-186-10	
10cc serological pipet	Falcon	357551	
18G 1.5in. Needle	BD	305190	
1mL Syringe	BD	309659	
24-well plate	Corning	3526	
25cc serological pipet	Falcon	356535	
25G 1in. Needle	BD	305125	
50cc tube	BD	352070	
Alcohol prep pads	Fisher Healthcare	NDC 69250-661-02	
Baytril (enrofloxacin) solution	Bayer Healthcare, LLC	NDC 0859-2267-01	
Black polyamide monofilament suture, 9-0	AROSurgical Instruments Corporation	T05A09N10-13	
C57BL/6, female	Jackson laboratories	664	6-8 weeks old
Citrate Buffer pH 6.0 20x concentrate	ThermoFisher	5000	
Colibri retractors	F.S.T	17000-04	
Cotton tipped applicators	Fisher scientific	23-400-118	
Cytokeratin 14 Monoclonal Antibody	ThermoFisher	MA5-11599	
Dumont #5 Forceps	F.S.T	11251-20	
Dumont #5/45 forceps	F.S.T	11251-35	
Dumont #7 - Fine Forceps	F.S.T	11274-20	
F4/80 Rat anti-mouse antibody	Bio-Rad	MCA497R	
Ficoll	Sigma	10831-100mL	
Fine scissors- Sharp-blunt	F.S.T	14028-10	
Fisherbrand Premium Cover Glasses	ThermoFisher	12-548-5M	

Fluoroshield Mounting Media with DAPI	Abcam	ab104139	
Goat-anti mouse IgG Secondary Antibody Alexa Fluor 594	ThermoFisher	A-11001	
Goat-anti Rabbit IgG Secondary Antibody Alexa Fluor 594	ThermoFisher	A-11012	
Goat-anti Rat IgG Secondary Antibody Alexa Fluor 647	ThermoFisher	A-21247	
Ibuprofen	Precision Dose, Inc	NDC 68094-494-59	
Iodine prep pads	Professional disposables international, Inc.	NDC 10819-3883-1	
Keratin 5 Polyclonal Antibody, Purified	BioLegend	905501	
Ketamine hydrochloride injection	Hospira Inc.	NDC 0409-2053	
Micro-Adson forceps	F.S.T	11018-12	
Microscope	Leica	M80	
Non-woven sponges	Covidien	441401	
Ophthalmic ointment	Dechra Veterinary products	NDC 17033-211-38	
PBS	Gibco	10010-023	
PET/PU (Polyethylene terephthalate & Polyurethane) scaffolds	Nanofiber solutions		Custom ordered
Petri dish	BD	353003	
RPMI 1640 Medium	Gibco	11875-093	
TISH Needle Holder/Forceps	Micrins	MI1540	
Trimmer	Wahl	9854-500	
Vannas-Tübingen Spring Scissors	F.S.T	15008-08	
Warm water recirculator	Gaymar	TP-700	
Xylazine sterile solution	Akorn animal health	NDC 59399-110-20	



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Author(s):

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's


expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:	Tendy Chiang	
Department:	Otolaryngology	
Institution:	Nationwide Children's Hospital	
Article Title:	Seeding and implantation of a biosynthetic tissue-engineered tracheal graft in a mouse model	
Signature:		Date: 9/30/2018

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Dear Dr. Wu,

We appreciate your time in reviewing our manuscript titled “Seeding and implantation of a biosynthetic tissue-engineered tracheal graft in a mouse model”. We have adjusted the manuscript to address the unit suggestions, removed trademarked words and have included more information regarding the safety and care of the animals as well as a step-by-step protocol for conducting the immunofluorescence. Additionally, we have selected the appropriate sections for filming. We look forward to your decision on the manuscript and are very grateful for your consideration for publishing in the Journal of Visualized Experiments.

Best regards,

Matthew Wiet

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

Manuscript was proofread for grammar and spelling.

2. Please use standard SI unit symbols and prefixes such as μL , mL, L, g, m, etc. Please use mL instead of cc.

Changes were made to remove "cc" and replaced it with "mL" (Lines 114, 132)

3. Please use h, min, s for time units.

Time units were changed in the appropriate places Protocol 2.3, 2.5, 2.6, 2.9, 3.2, 3.3, 4.1

4. JoVE cannot publish manuscripts containing commercial language. This includes company names of an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents. Examples of commercial language in your manuscript include Ficoll, Rotina 420R, Histopaque, Fisherbrand, etc.

Commercial language has been removed line 137, 141, 156-157, 183. 191-192, 215

5. There is a 2.75 page limit for filmable content. Please highlight 2.75 pages or less of the Protocol (including headings and spacing) in yellow that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol.

We feel that the important parts of this protocol are in the graft manufacturing (electrospinning and cell seeding) and the implantation procedure. We have highlighted these sections excluding the anesthesia/euthanasia portions.

6. Step 1.3: Please ensure that all text is written in imperative tense.

Thank you for noticing this, it has been adjusted

7. Step 5: Please rewrite the note as protocol steps. Please ensure that all text is written in imperative tense.

Thank you for the suggestion, Step 5 has been rewritten in protocol format. (Lines 239-263) Additionally, materials for this were added to the materials list.

8. For survival strategies, discuss post-surgical treatment of animal, including recovery conditions and treatment for post-surgical pain.

Recovery conditions have been added to 4.14. Pain treatment consists of close observation by the veterinary staff. If prolonged, euthanasia is indicated. Both of these points have been added as a note (Lines 233-235)

Discuss maintenance of sterile conditions during survival surgery.

A note has been added to the beginning of step 4.

Please specify that the animal is not left unattended until it has regained sufficient consciousness to maintain sternal recumbency.

Protocol 4.14 has been added to help clarify this.

Please specify that the animal that has undergone surgery is not returned to the company of other animals until fully recovered.

Language has been added to protocol 4.13 to reflect this.

9. Please do not highlight any steps describing euthanasia or anesthesia